Controlled-release particulate cytokine adjuvants for cancer therapy

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 7, Issue 4, 2007, Pages 266-270

  Egilmez, Nejat K ^a,c   Kilinc, Mehmet O ^a   Gu, Tao ^a   Conway, Thomas F ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Therapyx Inc   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; CANCER VACCINE; CELLULOSE; CHITIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; GOSERELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; LEUPRORELIN; LIPOSOME; LYMPHOTACTIN; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; POLYLACTIC ACID; POLYMER; RECOMBINANT CYTOKINE; TRIPTORELIN; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLODEX;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER REGRESSION; CANCER THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; EFFECTOR CELL; ENCAPSULATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; KAPOSI SARCOMA; KIDNEY CARCINOMA; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MEMORY CELL; MICROENVIRONMENT; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NONHUMAN; PROSTATE CANCER; REVIEW; SCID MOUSE; SINGLE DRUG DOSE; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; TUMOR XENOGRAFT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DELAYED-ACTION PREPARATIONS; HUMANS; NEOPLASMS;

EID: 37549028742     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153007782794335     Document Type: Review

References (63)

1. Dranoff, G. (2004) Nat. Rev. Cancer, 4, 11-22.
2. Salazar-Onfray, F.; Lopez, M.N. and Mendoza-Naranjo, A. (2007) Cytokine Growth Factor Rev., 18, 171-182.
3. Copier, J. and Dalgleish, A. (2006) Int. Rev. Immunol., 25, 297-319.
4. Podhajcer, O.L.; Lopez, M.V. and Mazzolini, G. (2007) Cytokine Growth Factor Rev., 18, 183-194.
5. Jonasch, E. and Haluska, F.G. (2001) Oncologist, 6, 34-55.
6. Rosenberg, S.A. (1988) Ann. Surg., 208(2), 121-135.
7. Smyth, M.J.; Cretney, E.; Kershaw, M.H. and Hayakawa, Y. (2004) Immunol. Rev., 202(1), 275-293.
8. Forni, G.; Giovarelli, M. and Santoni, A. (1985) J. Immunol., 134(2), 1305-1311.
9. Gallagher, G. and Zaloom, Y. (1994) Anticancer Res., 12(3), 1019-1024.
10. Brunda, M.J.; Luistro, L.; Warrier, R.R.; Wright, R.B.; Hubbard, B.R.; Murphy, M.; Wolf, S.F. and Gately, M.K. (1993) J. Exp. Med., 178(4), 1223-1230.
11. Morales, A.; Johnston, B.; Emerson, L. and Heaton, J.W. (1997) Urology, 50(4), 495-502.
12. Kowalzick L.; Rogozinski, T.; Wimheuer, R.; Pilz, J.; Manske, U.; Scholz, A.; Fierlbeck, G.; Mohr, P.; Ochsendorf, F.; Wagner, G.; Gaus, W.; Brzoska, J. and Jablonska, S. (2002) Eur. J. Dermatol., 12(6), 558-561.
13. Watanabe, N.; Yamauchi, N.; Maeda, M.; Neda, H.; Tsuji, Y.; Okamoto, T.; Tuji, N.; Akiyama, S., Sasaki, H. and Niitsu, Y. (1994) Oncology, 51(4), 360-365.
14. Davidson, J.A.; Musk, A.W.; Wood, B.R.; Morey, S.; Ilton, M.; Yu, L.L.;,Drury, P.; Shilkin, K. and Robinson, B.W. (1998) J. Immunother., 21(5), 389-398.
15. Scudeletti, M.; Fitaci, G.; Imro, M.A.; Motta, G.; Di Gaetano, M.; Pierri, I.; Tongiani, S.; Indiveri, F. and Puppo, F. (1993) Cancer Immunol. Immunother., 37(2), 119-124.
16. van Herpen, C.M.; Looman, M.; Zonneveld, M.; Scharenborg, N.; de Wilde, P.C.; van de Locht, L.; Merkx, M.A.; Adema, G.J. and de Mulder, P.H. (2004) Clin. Cancer Res., 10(8), 2626-2635.
17. Rook, A.H.; Wood, G.S.; Yoo, E.K.; Elenitsas, R.; Kao, D.M.; Sherman, M.L.; Witmer, W.K.; Rockwell, K.A.; Shane, R.B.; Lessin, S.R. and Vonderheid, E.C. (1999) Blood, 94(3), 902-908.
18. Parmiani, G.; Rodolfo, M. and Melani, C. (2000) Hum. Gene Ther., 11, 1269-1275.
19. Mach, N. and Dranoff, G. (2000) Curr. Opin. Immunol., 12, 571-575.
20. Ribas, A.; Butterfield, L.H.; Glaspy, J.A. and Economou, J.S. (2003) J. Clin. Oncol., 21, 2415-2432.
21. Dranoff, G. (2003) Oncogene, 22(20), 3188-3192.
22. Tai, K.F.; Chen, D.S. and Hwang, L.H. (2004) J. Biomed. Sci., 11(2), 228-238.
23. Le, H.N.; Lee, N.C.; Tsung, K. and Norton, J.A. (2001) J. Immunol., 167(12), 6765-6772.
24. Kilinc, M.O.; Aulakh, K.S.; Nair, R.E.; Jones, S.A.; Alard, P.; Kosiewicz, M.M. and Egilmez, N.K. (2006) J. Immunol., 177(10), 6962-6973.
25. Salem, M.L.; Gillanders, W.E.; Kadima, A.N.; El-Naggar, S.; Rubinstein, M.P.; Demcheva, M.; Vournakis, J.N. and Cole, D.J. (2006) J. Interferon Cytokine Res., 26(9), 593-608.
26. O'Hagan, D.T.; Singh, M. and Ulmer, J.B. (2006) Methods, 40(1), 10-19.
27. Ten Hagen, T.L. (2005) Methods Enzymol., 391, 125-145.
28. Hiemstra, C.; Zhong, Z.; Van Tomme, S.R.; van Steenbergen, M.J.; Jacobs, J.J.; Otter, W.D.; Hennink, W.E. and Feijen, J. (2007) J. Control. Release, 119(3), 320-327.
29. Moses, M.A.; Brem, H. and Langer, R. (2003) Cancer Cell, 4, 337-341.
30. Harper, E.; Dang, W.; Lapidus, R.G. and Garver, R.I. Jr. (1999) Clin. Cancer Res., 5, 4242-4248.
31. Fournier, E.; Passirani, C.; Montero-Menei, C.; Colin, N.; Breton, P.; Sagodira, S.; Menei, P. and Benoit, J.P. (2003) Cancer, 97, 2822-2829.
32. Liu, Z.; Ballinger, J.R.; Rauth, A.M.; Bendayan, R. and Wu, X.Y. (2003) J. Pharm. Pharmacol., 55(8), 1063-1073.
33. Raza, S.M.; Pradilla, G.; Legnani, F.G.; Thai, Q.A.; Olivi, A.; Weingart, J.D. and Brem, H. (2005) Expert Opin. Biol. Ther., 5(4), 477-494.
34. Gommersall, L.M.; Hayne, D.; Shergill, I.S.; Arya, M. and Wallace, D.M. (2002) Expert Opin. Pharmacother., 3(12), 1685-1692.
35. O'Hagan, D.T. and Valiante, N.M. (2003) Nat. Rev. Drug Discov., 2(9), 727-735.
36. Sinha, V.R. and Trehan, A. (2003) J. Control. Release, 90, 261-280.
37. Hora, M.S.; Rana, R.K.; Nunberg, J.H.; Tice, T.R.; Gilley, R.M. and Hudson, M.E. (1990) Biotechnology (N Y), 8(8), 755-758.
38. Golumbek, P.T.; Azhari, R.; Jaffee, E.M.; Levitsky, H.I.; Lazenby, A.; Leong, K. and Pardoll, D.M. (1993) Cancer Res., 53, 5841-5844.
39. Putney, S.D and Burke, P.A. (1998) Nat. Biotech., 16, 153-157.
40. Egilmez, N.K.; Jong, Y.S.; Iwanuma, Y.; Jacob, J.S.; Mathiowitz, E. and Bankert, R.B. (1998) Cancer Immunol. Immunother., 46, 21-24.
41. Shah, A.U. and D'Souza, M.J. (1999) Drug Dev. Ind. Pharm., 25, 995-1004.
42. Egilmez, N.K.; Jong, Y.S.; Sabel, M.S.; Jacob, J.S.; Mathiowitz, E. and Bankert, R.B. (2000) Cancer Res., 60, 3832-3837.
43. Pettit, D.K.; Lawter, J.R.; Huang, W.J.; Pankey, S.C.; Nightlinger, N.S.; Lynch, D.H.; Schuh, J.A.; Morrissey, P.J. and Gombotz, W.R. (1997) Pharm. Res., 14(10):1422-30.
44. Sharma, A.; Harper, C.M.; Hammer, L.; Nair, R.E.; Mathiowitz, E. and Egilmez, N.K. (2004) Cancer Biother. Radiopharm., 19(6), 764-769.
45. Hill, H.C.; Conway, T.F.; Sabel, M,S.; Jong, Y.S.; Mathiowitz, E Bankert, R.B. and Egilmez, N.K. (2002) Cancer Res., 62, 7254-7263.
46. Nair, R.E.; Jong, Y.S.; Jones, S.A.; Sharma, A.; Mathiowitz, E. and Egilmez, N.K. (2006) J. Immunother., 29(1), 10-20.
47. Nair, R.E.; Kilinc, M.O.; Jones, S.A. and Egilmez, N.K. (2006) J. Immunol., 176(12), 7325-7334.
48. Egilmez, N.K.; Jong, Y.S.; Hess, S.D.; Jacob, J.S.; Mathiowitz, E. and Bankert, R.B. (2000) J. Immunother., 23(2), 190-195.
49. Kuriakose, M.A.; Chen, F.-A.; Egilmez, N.K.; Jong, Y.S.; Mathiowitz, E.; DeLacure, M.D.; Hicks, W.L.; Loree, T.L. and Bankert, R.B. (2000) Head Neck, 22, 57-63.
50. Sugiyama, Y.; Kato, M.; Chen, F.-A.; Williams, S.S.; Kawaguchi, Y.; Miya, K.; Jong, Y.S.; Mathiowitz, E.; Egilmez, N.K. and Bankert, R.B. (2001) J. Immunother., 24(1), 37-45.
51. Hess, S.D.; Egilmez, N.K.; Bailey, N.; Anderson, T.M.; Mathiowitz, E.; Bernstein, S.H. and Bankert, R.B. (2003) J. Immunol., 170(1), 400-412.
52. Broderick, L.; Yokota, S.J.; Reineke, J.; Mathiowitz, E.; Stewart, C.C.; Barcos, M.; Kelleher, R.J. Jr. and Bankert, R.B. (2005) J. Immunol., 174(2), 898-906.
53. Broderick, L.; Brooks, S.P.; Takita, H.; Baer, A.N.; Bernstein, J.M. and Bankert, R-B. (2006) Clin. Immunol., 118(2-3), 159-169.
54. Sabel, M.S.; Skitzki, J.; Stoolman, L.; Egilmez, N.K.; Mathiowitz, E.; Bailey, N.; Chang, W.-J. and Chang, A. (2004) Ann. Surg. Oncol., 11(2), 147-156.
55. Arora, A.; Su, G.; Mathiowitz, E.; Reineke, J.; Chang, A.E. and Sabel, M.S. (2006) J. Surg. Oncol., 94(5), 403-412.
56. de Visser, K.E.; Eichten, A. and Coussens, L.M. (2006) Nat Rev. Cancer, 6, 24-37.
57. Crittenden, M.R.; Thanarajasingam, U.; Vile, R.G. and Gough, M.J. (2005) Immunology, 114, 11-22.
58. Cavallo, F.; Signorelli, P.; Giovarelli, M.; Musiani, P.; Modesti, A.; Brunda, M.J.; Colombo, M.P. and Forni, G. (1997) J. Natl. Cancer Inst., 89(14), 1049-1058.
59. Trinchieri, G. (2003) Nature Rev., 3, 133-146.
60. Watkins, S.K.; Egilmez, N.K.; Suttles, J. and Stout, R.D. (2007) J. Immunol., 178(3), 1357-1362.
61. Tsung, K.; Dolan, J.P.; Tsung, Y.L. and Norton, J.A. (2002) Cancer Res., 62(17), 5069-5075.
62. Ostrand-Rosenberg, S. (2004) Curr. Opin. Immunol., 16(2), 143-150.
63. Polak, L. and Turk, J.L. (1974) Nature, 249(458), 654-656.